ERS Genomics

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services 1 October 2024 -- Dublin, Ireland, and Montreal, Canada -- ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, today announced...

ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement

Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR...

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering 20 May 2024 -- Dublin, Ireland, and Rome, Italy -- ERS Genomics, the CRISPR licensing company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants...

ERS Genomics appoints John E Milad as Chief Executive Officer

13 May 2024 -- Dublin, Ireland -- ERS Genomics, the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25 years of experience as an executive leader, venture capitalist and investment banker focused on the life sciences and medical technology sectors. John E Milad As...

Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration

Patent CN201380038920.6 upheld in response to invalidation challenge 26 March 2024 – Dublin, Ireland – ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an...

Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement

CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model 13 March 2024 -- Tokyo, Japan, and Dublin, Ireland -- Ricoh Company today announced a non-exclusive licensing agreement in the US and Japan with ERS Genomics Limited for access to the foundational CRISPR/Cas9 genome editing technology patents managed by ERS...

ERS Genomics and StemSight sign CRISPR/Cas9 license agreement

·       License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness 17 January 2024 – Dublin, Ireland, and Tampere, Finland – ERS Genomics Limited, the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier,...
8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland

+353 (01) 539 0082